Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...